Open Access<p>Response and acquired resistance to savolitinib in a patient with pulmonary sarcomatoid carcinoma harboring <em>MET</em> exon 14 skipping mutation: a case report</p>
Author(s) -
Sen Han,
Jian Fang,
Shun Lü,
Linfang Wang,
Jing Li,
Min Cheng,
Yongxin Ren,
Weiguo Su
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s210365
Subject(s) - medicine , exon , lung cancer , kras , biopsy , lung , liquid biopsy , pathology , mutation , carcinoma , oncology , cancer , cancer research , gastroenterology , colorectal cancer , gene , biology , biochemistry
Pulmonary sarcomatoid carcinoma (PSC) is a rare and poorly differentiated type of non-small cell lung cancer (NSCLC) with specific characteristics, which usually presents a challenge in clinical practice. Mesenchymal-epithelial transition ( MET ) gene has been identified as a promising target for treatments in the past few years. Here, we report a case of a patient with PSC harboring MET exon 14 mutation, who responded to a novel MET inhibitor - savolitinib.